Vienna, November 19, 2020 – Sarcura GmbH, a Vienna-based biotech start-up, secures €2.5 million in its seed funding round from renowned venture capital investors including IST Cube, Nina Capital and Axilium Capital.
Sarcura is working on the development of an innovative manufacturing platform for autologous cell therapy. The interdisciplinary founding team combines microfluidics and microchip technology to revolutionize the industrial manufacturing of personalized cell therapy. In doing so, the company aims to fully automate the manufacturing of highly potent, live drugs through real-time process and inline quality control at the cellular level. Sarcura will use the investment to advance the development of its first product, a GMP cell sorter.
The Brandl & Talos transaction team consisted of Markus Arzt and Adrian Zuschmann.